Clinical trials: CD - Crohn's Disease
Crohn's Disease
A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease
The primary purpose of this multi-centre, double blind-study is to evaluate the clinical response of patients with moderate to severe Cohn's Disease (CD) following treatment with different doses and dose regimens of Olokizumab…
- Trial name
- NCT01635621
- Testing
- Olokizumab (OKZ)
- Sponsor
- UCB BIOSCIENCES GmbH
Inflammatory Bowel Disease, Intestinal Fistula
Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas
The objective of this study is to evaluate the safety and effectiveness of the experimental drug AST-120 in treating patients with mild to moderately severe Crohn's disease who have fistulas.
- Trial name
- NCT00321412
- Testing
- AST-120
- Where
- 88 sites in United States, Austria and 10 more
- Volunteers
- 191 people
- Sponsor
- Ocera Therapeutics
Crohn Disease, Colitis, Ulcerative
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Researchers want to learn more about tulisokibart (also known as MK-7240) in an extension study. Tulisokibart is a medicine designed to treat active, moderate to severe Crohn's disease (CD) and ulcerative colitis (UC).
- Trial name
- NCT06651281
- Testing
- Tulisokibart
- Where
- 37 sites in United States, Czechia and 5 more
- Volunteers
- 1,380 people
- Sponsor
- Merck Sharp & Dohme LLC
Ulcerative Colitis, Crohn's Disease
A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD)
This is a randomized, observer-blinded, placebo-controlled study to evaluate safety, tolerability, immunogenicity, and pharmacokinetics of repeat dosing of intravenous (IV) UTTR1147A.
- Trial name
- NCT02749630
- Testing
- UTTR1147A
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Crohn Disease
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
The purpose of this study is to compare the efficacy of treatment with ustekinumab or adalimumab in biologic naive participants with moderately-to-severely active Crohn's disease (CD) who have previously failed or were intolerant…
- Trial name
- SEAVUE (NCT03464136)
- Testing
- Ustekinumab (6 mg/kg), Ustekinumab (90 mg), Adalimumab (40 mg)
- Where
- 182 sites in United States, Australia and 16 more
- Volunteers
- 386 people
- Sponsor
- Janssen Scientific Affairs, LLC
Crohn Disease
Diet Intervention for Crohn's Disease Patient
The purpose of this study is to determine the effectiveness of a low-fat, high fiber diet (LFD) containing a minimal proportion of fat to improve gastrointestinal symptoms, quality of life and signs of inflammation in blood and…
- Trial name
- NCT04213729
- Testing
- Diet Counseling, CD LFD, Dyadic Psychological Support (DPS)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Miami
Crohn's Disease
The MOTOR-CD Trial
Both single-balloon enteroscopy (SBE) and novel motorized spiral enteroscopy (NMSE) are effective techniques for small bowel endoscopy in suspected Crohn's disease (CD).
- Trial name
- NCT05363930
- Testing
- Novel motorized spiral enteroscopy, Single balloon enteroscopy
- Where
- India
- Volunteers
- 128 people
- Sponsor
- Asian Institute of Gastroenterology, India
Crohn's Disease (CD)
Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease
The aim of the study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of study drug (BCD-261) in comparison with placebo and to characterize the dose-response relationship in patients…
- Trial name
- COMANDOR (NCT07078994)
- Testing
- anti-TL1A monoclonal antibody, low dose, anti-TL1A monoclonal antibody, medium dose, anti-TL1A monoclonal antibody, high dose
- Where
- 20 sites in Russia
- Volunteers
- 204 people
- Sponsor
- Biocad
Granulomatous Colitis, Crohn's Disease
An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease
The purpose of this study is to assess the safety and effectiveness of BMS-986165 compared to placebo in participants with moderately to severely active Crohn's Disease.
- Conditions
- Granulomatous Colitis, Crohn's Disease, Crohn's Enteritis, Granulomatous Enteritis
- Trial name
- NCT03599622
- Testing
- BMS-986165
- Where
- 259 sites in United States, Australia and 24 more
- Volunteers
- 239 people
- Sponsor
- Bristol-Myers Squibb
Crohn's Disease
Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease
This study aims to determine which of 3 doses of a non-absorbable antibiotic Rifaximin is most effective in treating active moderate Crohn's disease.
- Trial name
- NCT00528073
- Testing
- Rifaximin-EIR
- Where
- 57 sites in France, Germany and 5 more
- Volunteers
- 410 people
- Sponsor
- Alfasigma S.p.A.
Ulcerative Colitis, Crohn's Disease
Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201
This will be a single centre, Phase 1, Placebo-controlled, Randomized, Doubleblind, SAD \& MAD Study to Assess the Safety, Tolerability and PK of HM201 in Healthy Subjects.
- Trial name
- NCT05088369
- Testing
- HM201
- Where
- Australia
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Syneos Health
Crohn's Disease With Perianal Fistulas
Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn's
To assess whether a combination of ciprofloxacin and adalimumab is more effective than adalimumab alone for the treatment of perianal fistulas in Crohn's disease
- Trial name
- Adafi (NCT00736983)
- Testing
- adalimumab, ciprofloxacin
- Where
- 13 sites in Netherlands
- Volunteers
- 76 people
- Sponsor
- Foundation for Liver Research
Crohn Disease
A Study of Real-World Outcomes of People With Crohn's Disease (CD)
The main aim of this study is to compare long-term remission in participants receiving vedolizumab (VDZ) and those receiving ustekinumab (UST). In this study, the study doctors will review each participant's past medical records.
- Trial name
- EVOLVE (NCT05056441)
- Where
- 31 sites in Australia, Belgium and 1 more
- Volunteers
- 623 people
- Sponsor
- Takeda
Crohn's Disease, Vitamin D Deficiency
Vitamin D Supplementation as Non-toxic Immunomodulation in Children With Crohn's Disease
IBD is caused by an abnormal immune response to the gut bacteria in people who are genetically predisposed. There has been a huge increase in the number of people diagnosed with IBD since World War II, likely due to changes in…
- Trial name
- NCT01046773
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of California, Los Angeles
Inflammatory Bowel Diseases, Crohn Disease
Prevalence and Factors Associated With Sleep Disorders in Inflammatory Bowel Disease
Inflammatory bowel diseases (IBD) including Crohn's disease (CD) and ulcerative colitis (UC), are an inflammatory disease that can affect the entire digestive tract from the mouth to the anus for CD and the entire colon and…
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Sleep Disorder
- Trial name
- SOMMICI (NCT06439641)
- Testing
- Ulcerative colitis Disease Activity Index
- Where
- France
- Volunteers
- 300 people
- Sponsor
- CHU de Reims
Crohn's Disease
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label.
- Trial name
- CAPE (NCT02130362)
- Where
- 148 sites in United States, Bosnia and Herzegovina and 20 more
- Volunteers
- 1,446 people
- Sponsor
- AbbVie
Inflammatory Bowel Disease (IBD), Crohn Disease (CD)
PROactive and Early Infliximab Monitoring and OPTimization in Inflammatory Bowel Disease
Infliximab (IFX) is a Food and Drug administration (FDA)-appoved monoclonal antibody medication targeting tumor necrosis factor (TNF) widely used in inflammatory bowel disease (IBD) to treat intestinal inflammation and improve…
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC)
- Trial name
- PROMPT-IBD (NCT06758024)
- Testing
- Infliximab
- Where
- Chile
- Volunteers
- 72 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Crohn Disease
ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice
The purpose of this study is to describe physician-reported clinical effectiveness outcomes, as determined by Harvey-Bradshaw Index (HBI) assessment, in biologic-naive participants with CD over 12 months following treatment…
- Trial name
- EARLY-CD (NCT04349449)
- Where
- 14 sites in Canada
- Sponsor
- Takeda
Handgrip Strength
High-protein Oral Nutrition With HMB for Active CD Patients With Sarcopenia
The efficacy of B-hydroxy-β-methybutyrate in sarcopenia
- Trial name
- NCT07171593
- Testing
- HMB
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Crohn's Disease, CAM
Efficacy of Acupuncture and Moxibustion Treatment in Patients With Quiescent Crohn's Disease:Evaluation With fMRI
The purpose of this study is to determine whether acupuncture or moxibustion therapies are effective in the treatment of Crohn's disease.
- Trial name
- NCT01696838
- Testing
- electroacupuncture, moxibustion
- Where
- China
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute of Acupuncture, Moxibustion and Meridian
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.